Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Cash: 2014-2025

Historic Change in Cash for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to -$107.2 million.

  • Theravance Biopharma's Change in Cash fell 366.56% to -$107.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 413.40%. This contributed to the annual value of -$1.7 million for FY2024, which is 99.32% up from last year.
  • Latest data reveals that Theravance Biopharma reported Change in Cash of -$107.2 million as of Q3 2025, which was down 162.55% from $171.3 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Change in Cash registered a high of $331.2 million during Q3 2022, and its lowest value of -$120.4 million during Q4 2022.
  • Its 3-year average for Change in Cash is -$11.2 million, with a median of -$23.0 million in 2024.
  • Its Change in Cash has fluctuated over the past 5 years, first slumped by 2,607.53% in 2023, then soared by 2,387.22% in 2025.
  • Theravance Biopharma's Change in Cash (Quarterly) stood at -$31.5 million in 2021, then slumped by 282.59% to -$120.4 million in 2022, then skyrocketed by 73.30% to -$32.1 million in 2023, then spiked by 144.86% to $14.4 million in 2024, then slumped by 366.56% to -$107.2 million in 2025.
  • Its last three reported values are -$107.2 million in Q3 2025, $171.3 million for Q2 2025, and $72.8 million during Q1 2025.